LIM Domain Only 2 Protein Expression,LMO2germline Genetic Variation, and Overall Survival in Diffuse Large B-Cell Lymphoma in the Pre-Rituximab Era

Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2011.638717
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Prognostic Nomogram for Overall Survival in Patients With Diffuse Large B‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

A Multicentre Study of Primary Breast Diffuse Large B-Cell Lymphoma in the Rituximab Era

British Journal of Haematology
Hematology
2014English

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

The Kyoto Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma in the Rituximab Era

Blood
BiochemistryImmunologyCell BiologyHematology
2015English

Assessment Index of Clinical Transformation From Follicular Lymphoma (Fl) to Diffuse Large B-Cell Lymphoma (Dlbcl) in the Rituximab Era

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

The Genetic Landscape of Diffuse Large B-Cell Lymphoma

Seminars in Hematology
Hematology
2015English

Combination of BCL-2 and MYC Protein Expression Improves High-Risk Stratification in Diffuse Large B-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2015English

Diffuse Large B-Cell Lymphoma

2020English

The Rituximab Maintenance Therapy Improves Prognosis of Transformed Diffuse Large B Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy